Detailed view for LmjF.24.0420

Basic information

TDR Targets ID: 27557
Leishmania major, ubiquitin carboxyl-terminal hydrolase, putative,cysteine peptidase, Clan CA, family C12, putative
Source Database / ID:  TriTrypDB  GeneDB

pI: 4.7908 | Length (AA): 307 | MW (Da): 34445 | Paralog Number: 0

Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0

Druggability Group : DG2

Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable

Pfam domains

PF01088   Ubiquitin carboxyl-terminal hydrolase, family 1

Gene Ontology

Mouse over links to read term descriptions.
GO:0016579   protein deubiquitination  
GO:0004843   ubiquitin-specific protease activity  
GO:0005622   intracellular  
GO:0004221   ubiquitin thiolesterase activity  
GO:0006511   ubiquitin-dependent protein catabolic process  

Metabolic Pathways

This gene is not mapped to any metabolic pathway in KEGG.

Structural information

Modbase 3D models:

There are 4 models calculated for this protein. More info on these models, including the models themselves is available at: Modbase

Target Beg Target End Template Template Beg Template End Identity Evalue Model Score MPQS zDope
7 229 2etl (A) 2 221 22.00 0 1 0.9 -1.19
7 227 1xd3 (A) 5 227 25.00 0 1 1.09 -1.22
4 228 1xd3 (A) 2 228 25.00 0 1 1.0352 -0.73
6 304 4wlr (A) 6 318 41.00 0 1 1.39674 -0.29

Help me make sense of these data.

Target Beg: first modeled residue
Target End: last modeled residue
Template: template structure used for modelling (PDB accession and chain)
Template Beg: first template residue in target-template alignment
Template End: last template residue in target-template alignment
Identity: sequence identity
Evalue: E value for target-template hit
Model Score: GA341 score (>0.7 for reliable model)
MPQS: ModPipe Quality Score (>1.1 for reliable model)
zDope: zDope Score (negative for reliable model)

A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.

PDB Structures:

No structure availble in the PDB for this protein

Expression

Upregulation Percent Ranking Stage Dataset
Upper 60-80% percentile amastigotes, metacyclic. Fernandes MC
Show/Hide expression data references
  • Fernandes MC Dual Transcriptome Profiling of Leishmania-Infected Human Macrophages Reveals Distinct Reprogramming Signatures.

Orthologs

Ortholog group members (OG5_128387)

Species Accession Gene Product
Arabidopsis thaliana AT5G16310   ubiquitin thiolesterase UCH1
Arabidopsis thaliana AT1G65650   peptidase C12, ubiquitin carboxyl-terminal hydrolase 2
Brugia malayi Bm1_20630   ubiquitin C-terminal hydrolase UCH-L5
Candida albicans CaO19.3930   ubiquitin carboxyl-terminal hydrolase-like protein
Candida albicans CaO19.11412   ubiquitin carboxyl-terminal hydrolase-like protein
Caenorhabditis elegans CELE_C08B11.7   Protein UBH-4
Cryptosporidium hominis Chro.10139   UCHL5 protein
Cryptosporidium parvum cgd1_1170   ubiquitin C-terminal hydrolase
Dictyostelium discoideum DDB_G0285527   peptidase C12 family protein
Drosophila melanogaster Dmel_CG3431   Ubiquitin carboxy-terminal hydrolase L5 ortholog
Drosophila melanogaster Dmel_CG1950   Uch-L5-related
Echinococcus granulosus EgrG_000143100   ubiquitin carboxyl terminal hydrolase isozyme
Entamoeba histolytica EHI_140500   ubiquitin carboxyl-terminal hydrolase, putative
Echinococcus multilocularis EmuJ_000141500   ubiquitin carboxyl terminal hydrolase isozyme
Echinococcus multilocularis EmuJ_000143100   ubiquitin carboxyl terminal hydrolase isozyme
Homo sapiens ENSG00000116750   ubiquitin carboxyl-terminal hydrolase L5
Leishmania braziliensis LbrM.24.0420   ubiquitin carboxyl-terminal hydrolase, putative,cysteine peptidase, Clan CA, family C12, putative
Leishmania donovani LdBPK_240420.1   ubiquitin carboxyl-terminal hydrolase, putative
Leishmania infantum LinJ.24.0420   ubiquitin carboxyl-terminal hydrolase, putative,cysteine peptidase, Clan CA, family C12, putative
Leishmania major LmjF.24.0420   ubiquitin carboxyl-terminal hydrolase, putative,cysteine peptidase, Clan CA, family C12, putative
Leishmania mexicana LmxM.24.0420   ubiquitin carboxyl-terminal hydrolase, putative,cysteine peptidase, Clan CA, family C12, putative
Loa Loa (eye worm) LOAG_13247   ubiquitin C-terminal hydrolase UCH-L5
Mus musculus ENSMUSG00000018189   ubiquitin carboxyl-terminal esterase L5
Neospora caninum NCLIV_063760   hypothetical protein
Oryza sativa 4331185   Os02g0822200
Oryza sativa 4328506   Os02g0180100
Plasmodium berghei PBANKA_0930900   deubiquinating/deneddylating enzyme, putative
Plasmodium falciparum PF3D7_1117100   deubiquinating/deneddylating enzyme
Plasmodium knowlesi PKNH_0914800   deubiquinating/deneddylating enzyme, putative
Plasmodium vivax PVX_091485   ubiquitin C-terminal hydrolase, family 1, putative
Plasmodium yoelii PY04400   ubiquitin carboxyl-terminal hydrolase isozyme l5
Schistosoma japonicum Sjp_0060830   ko:K05610 ubiquitin carboxyl-terminal hydrolase L5, putative
Schistosoma mansoni Smp_083200.2   ubiquitinyl hydrolase-UCH37 (C12 family)
Schistosoma mansoni Smp_083200.1   ubiquitinyl hydrolase-UCH37 (C12 family)
Schmidtea mediterranea mk4.000177.03  
Trypanosoma brucei gambiense Tbg972.11.5810   ubiquitin carboxyl-terminal hydrolase, putative,cysteine peptidase, Clan CA, family C12, putative
Trypanosoma congolense TcIL3000.11.5350   ubiquitin carboxyl-terminal hydrolase, putative
Trypanosoma cruzi TcCLB.510945.10   ubiquitin carboxyl-terminal hydrolase, putative
Trypanosoma cruzi TcCLB.419703.20   ubiquitin carboxyl-terminal hydrolase, putative
Toxoplasma gondii TGME49_247240   ubiquitin carboxyl-terminal hydrolase, family 1 protein

Essentiality

LmjF.24.0420 has one or more orthologs with essentiality data
Gene/Ortholog Organism Phenotype Source Study
CELE_C08B11.7 Caenorhabditis elegans embryonic lethal wormbase
CELE_C08B11.7 Caenorhabditis elegans larval arrest wormbase
PBANKA_0930900 Plasmodium berghei Slow plasmo
TGME49_247240 Toxoplasma gondii Probably non-essential sidik
Show/Hide essentiality data references
  • alsford High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome Genome Res 2011, 21:915-924
  • nmpdr Genome-scale essentiality datasets from published studies (M. tuberculosis) National Microbial Pathogen Data Resource
  • neb C. elegans RNAi phenotypes Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs
  • keio Systematic single-gene knock-out mutants of E. coli K12 The Keio Collection
  • gerdes Experimental determination and system-level analysis of essential genes in E. coli MG1655 Gerdes et al., J Bacteriol. 2003 185:5673-84
  • sidik A Genome-wide CRISPR Screen in Toxoplasma Identifies Essential Apicomplexan Genes. Sidik, Saima M., et al. "A genome-wide CRISPR screen in toxoplasma identifies essential apicomplexan genes." Cell 166.6 (2016): 1423-1435.
  • wormbase C. elegans RNAi experiments WormBase web site, http://www.wormbase.org, release WS170
  • goodall The Essential Genome of Escherichia coli K-12 (Transposon directed high-throughput mutagenesis) Goodall, Emily CA, et al. "The essential genome of Escherichia coli K-12." mBio 9.1 (2018): e02096-17.
  • yeastgenome Systematic deletion of yeast genes Saccharomyces Genome Database
  • blattner Systematic mutagenesis of the E. coli (MG1655) genome J Bacteriol 2004, 186:4921-4930
  • plasmo Functional Profiling of a Plasmodium Genome Reveals an Abundance of Essential Genes. Bushell, Ellen, et al. "Functional profiling of a Plasmodium genome reveals an abundance of essential genes." Cell 170.2 (2017): 260-272.
  • shigen Profiling of E. coli Chromosome (PEC) National Institute of Genetics, Japan

Phenotypes and Validation (curated)

Annotated phenotypes:

Affected Entity Phenotypic quality Occurs in Occurs at Evidence Observed in Drugs/Inhibitors
growth (GO:0040007) decreased time (PATO:0000716) single cell organism (CARO:0000064) amastigote (BTO:0000062) inferred from bioassay (ECO:0000094) Leishmania mexicana 337527   561727   585910  
Annotator: aaronjr@u.washington.edu. Comment: Drug: 4174-73-6. chemical inhibition with known cysteine peptidase inhibitors leads to slow growth of Leishmania sp. in cell assay; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. References: 7179420
growth (GO:0040007) decreased time (PATO:0000716) single cell organism (CARO:0000064) promastigote (BTO:0001124) inferred from bioassay (ECO:0000094) Leishmania mexicana 337527   561727   585910  
Annotator: aaronjr@u.washington.edu. Comment: Drug: 4174-73-6. chemical inhibition with known cysteine peptidase inhibitors leads to slow growth of Leishmania sp. in cell assay; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. References: 7179420
catalytic activity (GO:0003824) decreased (PATO:0000468) in vitro (MI:0492) inferred from enzyme assay (ECO:0000005) Leishmania mexicana 337527   561727   585910  
Annotator: aaronjr@u.washington.edu. Comment: Drug: 4174-73-6. chemical inhibition with known cysteine peptidase inhibitors leads to reduced enzyme activity in vitro; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. References: 7179420
growth (GO:0040007) decreased time (PATO:0000716) single cell organism (CARO:0000064) amastigote (BTO:0000062) inferred from bioassay (ECO:0000094) Leishmania amazonensis No drug identifiers listed for this gene.
Annotator: aaronjr@u.washington.edu. Comment: L-Amino acid esters appear to be hydrolyzed by cysteine peptidase and lead to slow growth of Leishmania sp. in cell assay; . References: 1428504 2235078 2345655
growth (GO:0040007) decreased time (PATO:0000716) single cell organism (CARO:0000064) amastigote (BTO:0000062) inferred from bioassay (ECO:0000094) Leishmania mexicana No drug identifiers listed for this gene.
Annotator: aaronjr@u.washington.edu. Comment: chemical inhibition with known cysteine peptidase inhibitors leads to slow growth of Leishmania sp. in cell assay; . References: 2270108
catalytic activity (GO:0003824) decreased (PATO:0000468) in vitro (MI:0492) inferred from enzyme assay (ECO:0000005) Leishmania amazonensis 81384   576750  
Annotator: aaronjr@u.washington.edu. Comment: chemical inhibition with known cysteine peptidase inhibitors leads to reduced enzyme activity in vitro; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. References: 8023752
catalytic activity (GO:0003824) decreased (PATO:0000468) in vitro (MI:0492) inferred from enzyme assay (ECO:0000005) Leishmania major 81384   576750  
Annotator: aaronjr@u.washington.edu. Comment: chemical inhibition with known cysteine peptidase inhibitors leads to reduced enzyme activity in vitro; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. References: 8023752
growth (GO:0040007) decreased time (PATO:0000716) single cell organism (CARO:0000064) amastigote (BTO:0000062) host (GO:0018995) Leishmania donovani No drug identifiers listed for this gene.
Annotator: aaronjr@u.washington.edu. Comment: Drug: 81989-95-9. chemical inhibition with known cysteine peptidase inhibitors leads to slow growth of Leishmania sp. in vivo (balb/c mouse) and cure of parasite burden; also provided protection against further infection (partial vaccine); General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. References: 11238649
growth (GO:0040007) decreased time (PATO:0000716) single cell organism (CARO:0000064) amastigote (BTO:0000062) inferred from bioassay (ECO:0000094) Leishmania donovani No drug identifiers listed for this gene.
Annotator: aaronjr@u.washington.edu. Comment: Drug: 81989-95-9. chemical inhibition with known cysteine peptidase inhibitors leads to slow growth of Leishmania sp. in vivo (balb/c mouse) and cure of parasite burden; also provided protection against further infection (partial vaccine); General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. References: 11238649
growth (GO:0040007) decreased time (PATO:0000716) single cell organism (CARO:0000064) amastigote (BTO:0000062) host (GO:0018995) Leishmania tropica No drug identifiers listed for this gene.
Annotator: aaronjr@u.washington.edu. Comment: Drug: 233277-99-1. chemical inhibition with known cysteine peptidase inhibitors leads to slow growth of Leishmania sp. in vivo (balb/c mouse lesions) and reduced lesion size; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. References: 15172223
growth (GO:0040007) decreased time (PATO:0000716) single cell organism (CARO:0000064) amastigote (BTO:0000062) inferred from bioassay (ECO:0000094) Leishmania tropica No drug identifiers listed for this gene.
Annotator: aaronjr@u.washington.edu. Comment: Drug: 233277-99-1. chemical inhibition with known cysteine peptidase inhibitors leads to slow growth of Leishmania sp. in vivo (balb/c mouse lesions) and reduced lesion size; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. References: 15172223
growth (GO:0040007) decreased time (PATO:0000716) single cell organism (CARO:0000064) promastigote (BTO:0001124) inferred from bioassay (ECO:0000094) Leishmania tropica No drug identifiers listed for this gene.
Annotator: aaronjr@u.washington.edu. Comment: Drug: 233277-99-1. chemical inhibition with known cysteine peptidase inhibitors leads to slow growth of Leishmania sp. in cell assay; inhibitors overcome redundancy?; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. References: 15172223
growth (GO:0040007) decreased time (PATO:0000716) single cell organism (CARO:0000064) promastigote (BTO:0001124) inferred from bioassay (ECO:0000094) Leishmania donovani 0   6693   81384   236103   327961   376038   543486   543487   575389   575390   575391   576750  
Annotator: aaronjr@u.washington.edu. Comment: Drug: 22386-37-4; Drug: 36677-78-8; Drug: 52090-11-6; Drug: 98319-30-3; Drug: 300670-24-0; Drug: 302939-54-4; Drug: 303216-44-6; Drug: 309742-24-3; Drug: 312280-89-0; Drug: 315703-20-9; Drug: 320369-30-0; Drug: 322409-94-9; Drug: 330220-86-5; Drug: 335206-77-4; Drug: 347910-28-5; Drug: 352560-86-2; Drug: 363180-61-4; Drug: 413580-11-7; Drug: 416878-80-3; Drug: 419547-26-5; Drug: 428852-79-3; Drug: 825612-08-6; Drug: 825612-09-7; Drug: 825612-10-0. in silico virtual screening of falcipains lead to bioactive compounds against Leishmania promastigotes; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. References: 15588096
catalytic activity (GO:0003824) decreased (PATO:0000468) in vitro (MI:0492) inferred from in-silico analysis (ECO:0000043) Leishmania donovani 0   6693   81384   236103   327961   376038   543486   543487   575389   575390   575391   576750  
Annotator: aaronjr@u.washington.edu. Comment: Drug: 22386-37-4; Drug: 36677-78-8; Drug: 52090-11-6; Drug: 98319-30-3; Drug: 300670-24-0; Drug: 302939-54-4; Drug: 303216-44-6; Drug: 309742-24-3; Drug: 312280-89-0; Drug: 315703-20-9; Drug: 320369-30-0; Drug: 322409-94-9; Drug: 330220-86-5; Drug: 335206-77-4; Drug: 347910-28-5; Drug: 352560-86-2; Drug: 363180-61-4; Drug: 413580-11-7; Drug: 416878-80-3; Drug: 419547-26-5; Drug: 428852-79-3; Drug: 825612-08-6; Drug: 825612-09-7; Drug: 825612-10-0. in silico virtual screening of falcipains lead to bioactive compounds against cysteine protease in vitro; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. References: 15588096
catalytic activity (GO:0003824) decreased (PATO:0000468) in vitro (MI:0492) inferred from specific protein inhibition (ECO:0000020) Leishmania donovani 0   6693   81384   236103   327961   376038   543486   543487   575389   575390   575391   576750  
Annotator: aaronjr@u.washington.edu. Comment: Drug: 22386-37-4; Drug: 36677-78-8; Drug: 52090-11-6; Drug: 98319-30-3; Drug: 300670-24-0; Drug: 302939-54-4; Drug: 303216-44-6; Drug: 309742-24-3; Drug: 312280-89-0; Drug: 315703-20-9; Drug: 320369-30-0; Drug: 322409-94-9; Drug: 330220-86-5; Drug: 335206-77-4; Drug: 347910-28-5; Drug: 352560-86-2; Drug: 363180-61-4; Drug: 413580-11-7; Drug: 416878-80-3; Drug: 419547-26-5; Drug: 428852-79-3; Drug: 825612-08-6; Drug: 825612-09-7; Drug: 825612-10-0. in silico virtual screening of falcipains lead to bioactive compounds against cysteine protease in vitro; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. References: 15588096
growth (GO:0040007) decreased time (PATO:0000716) single cell organism (CARO:0000064) promastigote (BTO:0001124) inferred from bioassay (ECO:0000094) Leishmania donovani No drug identifiers listed for this gene.
Annotator: aaronjr@u.washington.edu. Comment: Drug: 2935-91-3; Drug: 24117-97-3; Drug: 98647-23-5; Drug: 198124-18-4; Drug: 256238-87-6; Drug: 257287-52-8; Drug: 263157-80-8; Drug: 294854-43-6; Drug: 303124-84-7; Drug: 303147-38-8; Drug: 321579-84-4; Drug: 331247-87-1; Drug: 337923-53-2; Drug: 338791-39-2; Drug: 675828-74-7; Drug: 676226-56-5; Drug: 678967-57-2; Drug: 681213-40-1; Drug: 686272-33-3; Drug: 696586-43-3; Drug: 705250-31-3; Drug: 708987-83-1; Drug: 831234-40-3; Drug: 882161-95-7; Drug: 882161-98-0; Drug: 882161-99-1; Drug: 882162-00-7; Drug: 882162-01-8; Drug: 882162-02-9; Drug: 882162-03-0; Drug: 882162-04-1; Drug: 882162-05-2; Drug: 882162-06-3; Drug: 882162-07-4; Drug: 882162-08-5; Drug: 882162-09-6; Drug: 882162-10-9; Drug: 882162-11-0; Drug: 882162-12-1; Drug: 882162-13-2; Drug: 882162-14-3. in silico virtual screening of falcipains lead to bioactive compounds against Leishmania promastigotes; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. References: 16509575
catalytic activity (GO:0003824) decreased (PATO:0000468) in vitro (MI:0492) inferred from in-silico analysis (ECO:0000043) Leishmania donovani No drug identifiers listed for this gene.
Annotator: aaronjr@u.washington.edu. Comment: Drug: 2935-91-3; Drug: 24117-97-3; Drug: 98647-23-5; Drug: 198124-18-4; Drug: 256238-87-6; Drug: 257287-52-8; Drug: 263157-80-8; Drug: 294854-43-6; Drug: 303124-84-7; Drug: 303147-38-8; Drug: 321579-84-4; Drug: 331247-87-1; Drug: 337923-53-2; Drug: 338791-39-2; Drug: 675828-74-7; Drug: 676226-56-5; Drug: 678967-57-2; Drug: 681213-40-1; Drug: 686272-33-3; Drug: 696586-43-3; Drug: 705250-31-3; Drug: 708987-83-1; Drug: 831234-40-3; Drug: 882161-95-7; Drug: 882161-98-0; Drug: 882161-99-1; Drug: 882162-00-7; Drug: 882162-01-8; Drug: 882162-02-9; Drug: 882162-03-0; Drug: 882162-04-1; Drug: 882162-05-2; Drug: 882162-06-3; Drug: 882162-07-4; Drug: 882162-08-5; Drug: 882162-09-6; Drug: 882162-10-9; Drug: 882162-11-0; Drug: 882162-12-1; Drug: 882162-13-2; Drug: 882162-14-3. in silico virtual screening of falcipains lead to bioactive compounds against cysteine protease in vitro; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. References: 16509575
catalytic activity (GO:0003824) decreased (PATO:0000468) in vitro (MI:0492) inferred from specific protein inhibition (ECO:0000020) Leishmania donovani No drug identifiers listed for this gene.
Annotator: aaronjr@u.washington.edu. Comment: Drug: 2935-91-3; Drug: 24117-97-3; Drug: 98647-23-5; Drug: 198124-18-4; Drug: 256238-87-6; Drug: 257287-52-8; Drug: 263157-80-8; Drug: 294854-43-6; Drug: 303124-84-7; Drug: 303147-38-8; Drug: 321579-84-4; Drug: 331247-87-1; Drug: 337923-53-2; Drug: 338791-39-2; Drug: 675828-74-7; Drug: 676226-56-5; Drug: 678967-57-2; Drug: 681213-40-1; Drug: 686272-33-3; Drug: 696586-43-3; Drug: 705250-31-3; Drug: 708987-83-1; Drug: 831234-40-3; Drug: 882161-95-7; Drug: 882161-98-0; Drug: 882161-99-1; Drug: 882162-00-7; Drug: 882162-01-8; Drug: 882162-02-9; Drug: 882162-03-0; Drug: 882162-04-1; Drug: 882162-05-2; Drug: 882162-06-3; Drug: 882162-07-4; Drug: 882162-08-5; Drug: 882162-09-6; Drug: 882162-10-9; Drug: 882162-11-0; Drug: 882162-12-1; Drug: 882162-13-2; Drug: 882162-14-3. in silico virtual screening of falcipains lead to bioactive compounds against cysteine protease in vitro; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. References: 16509575
growth (GO:0040007) decreased time (PATO:0000716) single cell organism (CARO:0000064) promastigote (BTO:0001124) inferred from bioassay (ECO:0000094) Leishmania major No drug identifiers listed for this gene.
Annotator: aaronjr@u.washington.edu. Comment: Drug: 872361-01-8; Drug: 872361-02-9; Drug: 886061-72-9; Drug: 886061-73-0; Drug: 886061-74-1; Drug: 886061-75-2; Drug: 886061-76-3; Drug: 886061-77-4; Drug: 886061-78-5; Drug: 886061-79-6; Drug: 886061-80-9; Drug: 886061-81-0; Drug: 886061-82-1; Drug: 886061-85-4; Drug: 886061-86-5; Drug: 886061-87-6; Drug: 886061-88-7; Drug: 886061-89-8; Drug: 886061-90-1; Drug: 886061-91-2; Drug: 886061-92-3; Drug: 886061-93-4; Drug: 886061-99-0; Drug: 886062-00-6; Drug: 886062-05-1; Drug: 886062-06-2; Drug: 886062-07-3; Drug: 886062-08-4; Drug: 886062-09-5; Drug: 886062-10-8; Drug: 886062-11-9; Drug: 886062-12-0; Drug: 886062-13-1; Drug: 886062-14-2; Drug: 886062-15-3; Drug: 886062-16-4; Drug: 886062-17-5; Drug: 906674-95-1. chemical inhibition with peptidomimetics and Aziridine-2,3-dicarboxylates leads to slow growth of Leishmania sp. in cell assay; General cysteine peptidase inhibition with anti-leishmanial activity; specific target unknown. References: 16801424

In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.

In any case, if you have information about papers containing relevant validation data for this target, please contact us.

Annotated validation

  • Validation: in vivo inhibition
  • annotated by: aaronjr@u.washington.edu.
  • References: 11238649 15172223

Associated compounds / Druggability

Known modulators for this target

Compound Source Reference
Curated by TDRTargets References
Curated by TDRTargets References
Curated by TDRTargets References
Curated by TDRTargets References
Curated by TDRTargets References
Curated by TDRTargets References
Curated by TDRTargets References
Curated by TDRTargets References
Curated by TDRTargets References
Curated by TDRTargets References
Curated by TDRTargets References
Curated by TDRTargets References
Curated by TDRTargets References
Curated by TDRTargets References

Predicted associations

By orthology with druggable targets
Species Known druggable target Linked compounds Reference
Homo sapiens ubiquitin carboxyl-terminal hydrolase L5 Compounds References
By sequence similarity to non orthologous druggable targets
No additional associated druggable targets
Obtained from network model

Ranking Plot

Putative Drugs List

Compound Raw Global Species
0.0089 0.3002 0.8467
0.0313 0.3034 0
0.0298 0.2906 0
0.0099 0.3002 0.8467
0.007 0.3002 0.8467
0.0313 0.3034 0
0.0125 0.3038 0.3038
0.0313 0.3034 0
0.0099 0.3002 0.8467
0.0313 0.3034 0
0.0313 0.3034 0
0.008 0.3002 0.8467
0.009 0.3002 0.8467
0.0303 0.3177 0.3156
0.0077 0.3002 0.8467
0.0303 0.3177 0.3156
0.0092 0.3002 0.8467
0.0298 0.2906 0
0.0313 0.3034 0

Assayability

Assay information

No assay information for this target.

Reagent availability

No reagent availability information for this target.

Bibliographic References

11 literature references were collected for this gene.

If you have references for this gene, please enter them in a user comment (below) or Contact us.

User comments

No user comments are available for this gene. Log in to add comments, or register.

Enter your comment

User ()
Gene identifier LmjF.24.0420 (Leishmania major), ubiquitin carboxyl-terminal hydrolase, putative,cysteine peptidase, Clan CA, family C12, putative
Title for this comment
Comment